Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From RxSight Inc.
China biotechs blossom with millions in new funding for antibody developer Adagene and diabetes drug maker Hua Medicine, and a planned CNY5.7bn Shanghai listing for WuXi Apptec. However, national innovation darling Innovent Bio has withdrawn its PD-1 approval filing, dealing a setback to a crowded area.
Competition in the retinal implant market heats up as Pixium CE marks its second-generation bionic vision system, designed to offer key advantages including higher resolution and explantability.
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
In the ophthalmic device sector, intraocular lens surgery is expanding way beyond the cataract market with paradigm shifting technology. The vast presbyopia market now has an FDA-approved "corneal inlay" option, micro invasive glaucoma surgery has created an entirely new device segment, and corneal cross-linking has the potential to transcend its role as an effective treatment for a corneal disease to possibly being the next big thing in the non-surgical treatment of refractive errors.
- Medical Devices
- Implantable Devices
- Other Names / Subsidiaries
- Calhoun Vision, Inc.